| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 11, 2026 |
| Accession Number: | 0001213900-26-052963 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 11, 2026 |
| Accession Number: | 0001213900-26-052963 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom’s Public Sector Marketplace; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, July 07, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix’s previously announced pending acquisition. Realbotix has announced a partnership with Bloom Procu
Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall 2026; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, June 24, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix’s previously announced pending acquisition. Realbotix has launched Optio, its AI-powered teacher’s assistant, in a pilot program a
Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company"), a leading developer of humanoid robots and AI systems designed for human interaction across enterprise and consumer environments, reports its interim financial results for the three and six months ended March 31, 2026 ("Q2-2026"). All dollar figures are reported in United States dollars ("USD"), unless otherwise stated. Q2-2026 Financial and Operating Highlights For the three and six months ended March 31, 2026, the Company generated revenue of $225,000 and $578,000, respectively, compared to $727,000 and $1,543,000 for the corresponding periods in the prior fiscal year. The decline in revenue i
425 - Onconetix, Inc. (0001782107) (Subject)
425 - Onconetix, Inc. (0001782107) (Subject)
424B3 - Onconetix, Inc. (0001782107) (Filer)
Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company"), a leading developer of humanoid robots and AI systems designed for human interaction across enterprise and consumer environments, reports its interim financial results for the three and six months ended March 31, 2026 ("Q2-2026"). All dollar figures are reported in United States dollars ("USD"), unless otherwise stated. Q2-2026 Financial and Operating Highlights For the three and six months ended March 31, 2026, the Company generated revenue of $225,000 and $578,000, respectively, compared to $727,000 and $1,543,000 for the corresponding periods in the prior fiscal year. The decline in revenue i
Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising
SC 13G - Onconetix, Inc. (0001782107) (Subject)
SC 13D - Onconetix, Inc. (0001782107) (Subject)
SC 13D - Onconetix, Inc. (0001782107) (Subject)